Grindex...a leading pharmaceutical company in the Baltic region.

We aim to maintain our position as the leading pharmaceutical company in the Baltic region. We will achieve this not only by continuing to develop our own premium-quallity products, but we will also actively seekpartners from abroad with whom we can cooperate, thereby harnessing the power of the new market economy to the benefit of all.

In 1996 "GRINDEKS" celebrated 50 years anniversary since its foundation and 5 years of the Pharmaceutical Company "GRINDEKS".

The name of the Joint Stock Company "GRINDEKS" was chosen to distinguish the first Latvian scientist Professor David Hieronim Grindelis - chemist, pharmacist, naturalist and physician of the Latvian origin (1776-1836).

There were 613 employees at "GRINDEKS" in 1997 and turnover 14.90 million USD. "GRINDEKS" manufactures more than 100 products. During last five years "GRINDEKS" sales volume has grown for about 25% every year.

grindex_2.jpg (20686 bytes)
Public Joint Stock Company “Grindeks”, administrative building.

Main directions of activities of the state JSC “GrindeKS”

1. Development, production and promotion in the market of final dosage formulations - tablets, capsules, injectables, lyophilised pharmaceuticals, infusion solutions.

2. Development and production of active substances and their semi-products.

3. Investigation of new pharmaceuticals in cooperation with the research institutes of the Latvian Academy of Sciences and Medical Academy of Latvia, clinics and hospitals.

4. Promotion in the market and distribution of the pharmaceuticals of other companies.

grindex_3.jpg (18734 bytes)
GRINDEKS products.

Market strategy

"GRINDEKS" strategy in the market is oriented to the customer, providing the needs of the physician, pharmacist and patient.

Its sales are located in four geographical regions - Baltic countries, CIS countries, Japan and Central Europe.

"GRINDEKS" sales in Latvia make about 30% of the total company's sales, which is 5-7% of the Latvian market share.

In Baltic countries - 47% from the total sales volume.

In Russia and other CIS countries - 29% from the total sales volume.

Market in Japan is connected mainly with the sales of Ftorafur active substance, which is company's original product. First contracts on the export of Ftorafur were signed in 1972 and they are renewed from year to year. In 1996 sales of Ftorafur to Japan made 23% of the total company's sales volume.

Quality assurance

The quality of the company's activity is the quality of its products, their correspondence to the demands of the appropriate state health authorities and customer demands.

Good Manufacture Practice is introduced at "GRINDEKS" and it regulates: the production technological process; demands to the quality control of this process; requirements to the staff, facilities and equipment.

“Grindeks” cooperation partners and main cooperation fields

"Johnson&Johnson", USA

Product distribution since 1993, packaging and sales on license since 1995.

Distribution in all the Baltic states of five Tylenol line products - Tylenol Extra Strength, Tylenol Cold, Tylenol PM, Junior Strength Tylenol, Children's Tylenol.

grindex_1.jpg (21170 bytes)
Packaging tablets.

Dynamic marketing policy in the result of which Tylenol has gained strong position in the Latvian pharmaceutical market.

"Merck Generics", UK

Packaging on license of seven products at "GRINDEKS", with future whole production process of the products.

Agreements on the packaging of four new products (captopril, ranitidine, diltiazem, amoxycillin).

"Sanofi-Winthrop-Chinoin", France

Distribution of the products and consignment stock at "GRINDEKS" since 1994.

Packaging agreement on several products.

"Boehringer Ingelheim", Germany

Starting of the packaging for the Baltic market in 1997.

"Legosan AB", Sweden

Vitamin line products from which two are packed at "GRINDEKS", six at "LEGOSAN" for "GRINDEKS".

Agreements on the technology transfer for all these products to "GRINDEKS".

"Ilsanta UAB", Iceland

Agreement on strategic alliance with new factory of I.V. solutions "Icelandic-Lithuania".

"SAWAI Pharmaceutical Co. Ltd.", Japan

Production, packaging and distribution of three products on license.